Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.

Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.

Abstract: A composition useful for cosmetic treatment of the skin containing N-acetylglucosamine and an alkaline metal sulphate in equivalent mass ratios between 1:0.5 and 1:3, optionally in association with hyaluronic acid or a salt thereof.

Abstract: Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112° C. and melting with decomposition at about 400° C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.

Abstract: The present invention refers to a transdermal patch for the release of Estradiol and at least one progestogen agent through the skin, comprising or consisting of an outer backing foil, a matrix and a protective liner wherein a) the Estradiol and the progestogen agent(s) are present in the matrix in an oversaturated solution, b) the matrix contains 1 to 5 wt% activated SiO2, and c) the matrix has a moisture content of less than 0.7 wt.-%. The patch can be used for hormonal replacement therapy.

Abstract: The invention concerns a transdermal patch for the release through the skin of estradiol and a progestogen agent and a process for its production.